key: cord-0743397-o0bt8rrw authors: Matin, Somayeh; Talei, Sahand; Dalimi, Abdolhossein; Dadkhah, Masoomeh; Ghorbani, Maryam; Molaei, Soheila title: COVID-19 and Hydatidosis Infections: Is There Any Relationship? date: 2021 journal: Iran J Parasitol DOI: 10.18502/ijpa.v16i2.6287 sha: eb54826fdbc8cea7a30913fd097d3db6fc6d4c26 doc_id: 743397 cord_uid: o0bt8rrw nan The results obtained from following up 38 hydatidosis patients, that none of them contracted COVID-19. This result is more interesting when we consider that the families (including father, mother, etc.) of 8 patients with pulmonary hydatidosis have had active COVID-19, tested by PCR, and the results all of these 8 cases were negative. On the other hand, the survey of the patients' treatment history indicated that all of them had history of using albendazole at a dose of 400 mg twice daily for 28 days, then 14 drug-free days for two repeated period. Also, anti-hydatid antibodies of 150 active COVID-19 patients were negative. The question is why patients with COVID-19 in Ardabil Province were negative for antihydatid antibodies, while 1.79-11.07% of the people in this province are positive (1, 2)? Also, why none of the people with a history of hydatidosis have not infected with COVID-19, while some of them were in direct contact with infected people? Is it possible that hydatid cyst infection prevents COVID-19 infection? Instances of COVID -19 and malaria co-infection (3) as well as COVID-19 with different types of pathogens of respiratory tract have also been reported in the literature (4) . Two possibilities are at issue here: either there is an interaction between hydatid cyst antigens and coronavirus proteins, which there is no information; or the consumption of albendazole by hydatidosis patients has protected them against COVID-19. In worms and covid19 coinfection, it has been reported that immune responses become modified to the advantage of the host (5). Coinfection with Schistosoma mansoni and coronavirus decreases the severity of the disease in mice (6). Also, acute or chronic helminthic infections are believed to decrease the levels of proinflammatory cytokines implicated in COVID-19 severe cases, the type1 immunity response cytokines and therefore may improve morbidity and mortality of patients (7) . However, type 2 responses in COVID-19 infection, also play pivotal roles in progression and pulmonary involvement, making this issue a lot more sophisticated to understand whether helminthic infection could improve or intensify disease processes. Use of drugs like albendazole in hydatid cyst patients might be the reason for their protection against COVID-19. It has recently been suggested that the use of fenbendazole and other drugs of this category including mebendazole and albendazole could effectively protect people against COVID-19 (8). In conclusion, our study showed a possible relationship between anti-hydatid antibody or hydatid antigens and COVID-19 infection. Although, the authors suggest large scale studies to be conducted. Moreover, it is recommended that the effects of albendazole and also, mebendazole on SARS-CoV-2 to be investigated in both in-vitro and in-vivo and also clinical trials studies on COVID-19 patients. Epidemiology of echinococcosis in Iran: A systematic review and meta-analysis The seroprevalence of human cystic echinococcosis in Iran: A systematic review and meta-analysis study Malaria and parasitic neglected tropical diseases: Potential syndemics with covid-19? Co-infection with respiratory pathogens among covid-2019 cases Will helminth co-infection modulate covid-19 severity in endemic regions? Helminth-induced il-4 expands bystander memory cd8+ t cells for early control of viral infection Helminth coinfection and covid-19: An alternate hypothesis The authors declare that there is no conflict of interests.